Cancer drug Avastin may cause kidney damage, study finds

Jun 25, 2010 By Delthia Ricks

A widely prescribed cancer drug noted for its ability to choke off blood vessels that help tumors grow can cause significant kidney damage in some patients, a team of Long Island scientists has found.

Kidney problems are the second serious condition linked to and pinpointed in research conducted by Dr. Shenghong Wu and colleagues at Stony Brook University Medical Center. Last year Wu and his team found some patients on the drug were at elevated risk of intestinal perforations.

"This is a drug we use clinically for a lot of tumors -- lung cancer, kidney cancer, ," Wu said in an interview. "The safety is something we are researching. But this drug is used successfully and that is why we are studying it."

Reporting in this month's issue of the Journal of the American Society of Nephrology, Wu wrote that patients on Avastin were at increased risk of severe protein loss from the kidneys, which can lead to permanent damage. Overall, patients on Avastin were at a fourfold risk for protein loss and , depending on dosage and the type of cancer.

In terms of incidence, 10 percent of patients being treated with the drug for kidney cancer suffered organ damage and were at highest risk.

Avastin is a product of California-based biotech giant Genentech and was approved in 2004. It joined a burgeoning class of known as "targeted therapies" because unlike broad-spectrum chemotherapy, which attacks all cells, targeted drugs zero in on the cancer-causing mechanism, leaving healthy cells unscathed.

Avastin blunts the growth of tumor blood vessels, which allow the cancer to draw nutrients from the host's blood.

It's also used to treat patients with eye conditions such as macular degeneration and diabetic retinopathy. When injected directly into the eyes it destroys errant blood vessels that damage vision.

But for cancer patients, Avastin -- which can cost as much as $50,000 a year -- already carries a so-called black-box warning from the U.S. Food and Drug Administration, the agency's highest level of caution because of problems that emerged after its approval, experts said. The drug can cause hemorrhaging in some patients and seriously interferes with wound healing in those who've undergone surgery.

Wu, however, is among the many doctors who strongly defends Avastin's use. "We don't think it's a bad drug because it helps patients control cancer," he said.

Dr. Neil Segal, a cancer specialist at Memorial Sloan-Kettering Cancer Center in Manhattan, agrees the medication's benefits outweigh its risks. "Avastin when added to certain chemotherapies can help many patients.

"These are potential side effects," he said of problems uncovered in Wu's research. "Clinicians need to be aware of them and recognize them if they occur."

Explore further: India's meth addiction grows as criminals tap chemical hub

5 /5 (3 votes)
add to favorites email to friend print save as pdf

Related Stories

Popular cancer drug can cause kidney damage

Jun 10, 2010

The widely used cancer drug bevacizumab may cause severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment, according to a study ...

Anti-cancer drug damages brain vessels

Feb 11, 2008

New research may help explain why an anti-cancer drug causes potentially fatal brain inflammation in certain patients. Scientists at Harvard Medical School mimicked the drug's activity in mice and found that it damaged the ...

Novel drug combo improves breast cancer survival

Dec 11, 2009

(AP) -- Some women with very advanced breast cancer may have a new treatment option. A combination of two drugs that more precisely target tumors significantly extended the lives of women who had stopped responding to other ...

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

fixer
not rated yet Jun 27, 2010
It does extend life, but removes the quality and dignity.
A horrible drug, if they paid me $50,000 it wouldn't be worth it!